{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:14:05Z","timestamp":1789190045703,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1124\/jpet.105.089326","type":"journal-article","created":{"date-parts":[[2005,11,16]],"date-time":"2005-11-16T19:49:17Z","timestamp":1132170557000},"page":"1265-1277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4 H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine"],"prefix":"10.1016","volume":"315","author":[{"given":"Kurt","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Benvenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"Bymaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Calligaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie F.","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Hemrick-Luecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionna M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Nisenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Schaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Tupper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd R.","family":"Wiernicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.105.089326_bib1","doi-asserted-by":"crossref","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, and Weiden PJ (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156: 1686\u20131696.","DOI":"10.1176\/ajp.156.11.1686"},{"key":"10.1124\/jpet.105.089326_bib2","doi-asserted-by":"crossref","unstructured":"Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, and Hamilton S (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111\u2013123.","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"10.1124\/jpet.105.089326_bib3","doi-asserted-by":"crossref","unstructured":"Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, et al. (2002) Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018\u20131028.","DOI":"10.1176\/appi.ajp.159.6.1018"},{"key":"10.1124\/jpet.105.089326_bib4","doi-asserted-by":"crossref","unstructured":"Bunney BS, Walters JR, Roth RH, and Aghajanian GK (1973) Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560\u2013571.","DOI":"10.1016\/S0022-3565(25)29539-8"},{"key":"10.1124\/jpet.105.089326_bib5","doi-asserted-by":"crossref","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, and Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381\u2013389.","DOI":"10.1124\/jpet.102.033175"},{"key":"10.1124\/jpet.105.089326_bib6","unstructured":"Bylund DB and Snyder SH (1976) Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 12: 568\u2013580."},{"key":"10.1124\/jpet.105.089326_bib7","doi-asserted-by":"crossref","unstructured":"Bymaster FP, Hemrick-Luecke SK, Perry KW, and Fuller RW (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124: 87\u201394.","DOI":"10.1007\/BF02245608"},{"key":"10.1124\/jpet.105.089326_bib8","doi-asserted-by":"crossref","unstructured":"Bymaster FP, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, and Calligaro DO (1999) Olanzapine: a basic science update. Br J Psychiatry 174 (Suppl 37): 36\u201340.","DOI":"10.1192\/S0007125000293653"},{"key":"10.1124\/jpet.105.089326_bib9","doi-asserted-by":"crossref","unstructured":"Carpenter JW, Laethem C, Hubbard FR, Eckols TK, Baez M, McClure D, Nelson DL, and Johnston PA (2002) Configuring radioligand receptor binding assays for HTS using scintillation proximity assay technology. Methods Mol Biol 190: 31\u201349.","DOI":"10.1385\/1-59259-180-9:031"},{"key":"10.1124\/jpet.105.089326_bib10","doi-asserted-by":"crossref","unstructured":"Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099\u20133108.","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"10.1124\/jpet.105.089326_bib11","doi-asserted-by":"crossref","unstructured":"Chiodo LA and Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607\u20131619.","DOI":"10.1523\/JNEUROSCI.03-08-01607.1983"},{"key":"10.1124\/jpet.105.089326_bib12","doi-asserted-by":"crossref","unstructured":"Crawford AMK, Beasley CM, and Tollefson GD (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26: 41\u201354.","DOI":"10.1016\/S0920-9964(97)00036-4"},{"key":"10.1124\/jpet.105.089326_bib13","doi-asserted-by":"crossref","unstructured":"De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, and Luyten WH (1993) Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun 197: 1601\u20131608.","DOI":"10.1006\/bbrc.1993.2662"},{"key":"10.1124\/jpet.105.089326_bib14","doi-asserted-by":"crossref","unstructured":"Dourish CT (1995) Multiple serotonin receptors: opportunities for new treatments for obesity? Obes Res 4: 449S\u2013462S.","DOI":"10.1002\/j.1550-8528.1995.tb00212.x"},{"key":"10.1124\/jpet.105.089326_bib15","doi-asserted-by":"crossref","unstructured":"Fadel J, Bubser M, and Deutch AY (2002) Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 22: 6742\u20136746.","DOI":"10.1523\/JNEUROSCI.22-15-06742.2002"},{"key":"10.1124\/jpet.105.089326_bib16","doi-asserted-by":"crossref","unstructured":"Fell MJ, Neill JC, and Marshall KM (2004) Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. Eur Neuropsychopharmacol 14: 385\u2013392.","DOI":"10.1016\/j.euroneuro.2003.12.001"},{"key":"10.1124\/jpet.105.089326_bib17","doi-asserted-by":"crossref","unstructured":"Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al. (1994) The \u03b11-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human \u03b11c subtype. Mol Pharmacol 45: 703\u2013708.","DOI":"10.1016\/S0026-895X(25)10156-9"},{"key":"10.1124\/jpet.105.089326_bib18","doi-asserted-by":"crossref","unstructured":"Fuller RW and Perry KW (1989) Effects of buspirone and its metabolite, 1-(2-pyrimidinyl) piperazine, on brain monoamines and metabolites. J Pharmacol Exp Ther 248: 50\u201356.","DOI":"10.1016\/S0022-3565(25)23676-X"},{"key":"10.1124\/jpet.105.089326_bib19","doi-asserted-by":"crossref","unstructured":"Greengrass P and Bremner R (1979) Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol 55: 323\u2013326.","DOI":"10.1016\/0014-2999(79)90202-4"},{"key":"10.1124\/jpet.105.089326_bib20","doi-asserted-by":"crossref","unstructured":"Hall H, Kohler C, Gawell L, Farde L, and Sedvall G (1988) Raclopride, a new selective ligand for the dopamine-D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 12: 559\u2013568.","DOI":"10.1016\/0278-5846(88)90001-2"},{"key":"10.1124\/jpet.105.089326_bib21","doi-asserted-by":"crossref","unstructured":"Halme M, Sjoholm B, Savola JM, and Scheinin M (1995) Recombinant human alpha 2-adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 as radioligands. Biochim Biophys Acta 1266: 207\u2013214.","DOI":"10.1016\/0167-4889(95)90410-I"},{"key":"10.1124\/jpet.105.089326_bib22","doi-asserted-by":"crossref","unstructured":"Hemrick-Luecke SK and Evans DC (2002) Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT) 2 receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT2A receptor mediation of the HPA axis. Neuropharmacology 42: 162\u2013169.","DOI":"10.1016\/S0028-3908(01)00166-6"},{"key":"10.1124\/jpet.105.089326_bib23","doi-asserted-by":"crossref","unstructured":"Henderson DC (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16: 77\u201389.","DOI":"10.2165\/00023210-200216020-00001"},{"key":"10.1124\/jpet.105.089326_bib24","doi-asserted-by":"crossref","unstructured":"Hirst WD, Minton JA, Bromidge SM, Moss SF, Latter AJ, Riley G, Routlledge C, Middlemiss DN, and Price GW (2000) Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue. Br J Pharmacol 130: 1597\u20131605.","DOI":"10.1038\/sj.bjp.0703458"},{"key":"10.1124\/jpet.105.089326_bib25","doi-asserted-by":"crossref","unstructured":"Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, Gibbs EM, Zawalich WS, and Rollema H (2005) Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54: 1552\u20131558.","DOI":"10.2337\/diabetes.54.5.1552"},{"key":"10.1124\/jpet.105.089326_bib26","doi-asserted-by":"crossref","unstructured":"Kalkman HO, Neumann V, Nozulak J, and Tricklebank MD (1998) Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur J Pharmacol 343: 201\u2013207.","DOI":"10.1016\/S0014-2999(97)01554-9"},{"key":"10.1124\/jpet.105.089326_bib27","doi-asserted-by":"crossref","unstructured":"Kapur S, Langlois X, Vinken P, Megens AAHP, deCoster R, and Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302: 1129\u20131134.","DOI":"10.1124\/jpet.102.035303"},{"key":"10.1124\/jpet.105.089326_bib28","doi-asserted-by":"crossref","unstructured":"Kapur S, Zipursky RB, and Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry 156: 286\u2013293.","DOI":"10.1176\/ajp.156.2.286"},{"key":"10.1124\/jpet.105.089326_bib29","doi-asserted-by":"crossref","unstructured":"Karoum F, Chrapusta SJ, and Egan MF (1994) 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex\u2014reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens and striatum by a simple two pool model. J Neurochem 63: 972\u2013979.","DOI":"10.1046\/j.1471-4159.1994.63030972.x"},{"key":"10.1124\/jpet.105.089326_bib30","doi-asserted-by":"crossref","unstructured":"King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, and Fone KCF (2004) 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation\u2014an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47: 195\u2013204.","DOI":"10.1016\/j.neuropharm.2004.03.012"},{"key":"10.1124\/jpet.105.089326_bib31","doi-asserted-by":"crossref","unstructured":"Kinon BJ, Gilmore JA, Liu H, and Halbreich UM (2003) Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28: 69\u201382.","DOI":"10.1016\/S0306-4530(02)00128-2"},{"key":"10.1124\/jpet.105.089326_bib32","doi-asserted-by":"crossref","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, and Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519\u2013526.","DOI":"10.1038\/sj.npp.1300027"},{"key":"10.1124\/jpet.105.089326_bib33","doi-asserted-by":"crossref","unstructured":"Malmberg A and Mohell N (1995) Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides. J Pharmacol Exp Ther 274: 790\u2013797.","DOI":"10.1016\/S0022-3565(25)10626-5"},{"key":"10.1124\/jpet.105.089326_bib34","doi-asserted-by":"crossref","unstructured":"Marder SR (1999) Limitations of dopamine-D2 antagonists and the search for novel antipsychotic strategies. Neuropsychopharmacology 21: S117\u2013S121.","DOI":"10.1016\/S0893-133X(99)00105-0"},{"key":"10.1124\/jpet.105.089326_bib35","doi-asserted-by":"crossref","unstructured":"Masaki T, Yoshimatsu H, Chiba S, Watanabe T, and Sakata T (2001) Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity and UCP family in mice. Diabetes 50: 385\u2013391.","DOI":"10.2337\/diabetes.50.2.385"},{"key":"10.1124\/jpet.105.089326_bib36","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Matsubara S, and Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 p Ki values. J Pharmacol Exper Ther 251: 238\u2013246.","DOI":"10.1016\/S0022-3565(25)20710-8"},{"key":"10.1124\/jpet.105.089326_bib37","doi-asserted-by":"crossref","unstructured":"Moore NA (1999) Behavioral pharmacology of the new generation of antipsychotic agents. Br J Psychiatry 174 (Suppl 38): 5\u201311.","DOI":"10.1192\/S0007125000298061"},{"key":"10.1124\/jpet.105.089326_bib38","unstructured":"Motulsky H (1999) Fitting curves with nonlinear regression, in Analyzing Data with GraphPad Prism, pp. 199\u2013209, GraphPad Software, Inc, San Diego, CA."},{"key":"10.1124\/jpet.105.089326_bib39","doi-asserted-by":"crossref","unstructured":"Nelson DL, Lucaites VL, Wainscott DB, and Glennon RA (1999) Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT(2B) and 5-HT2C receptors. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 359: 1\u20136.","DOI":"10.1007\/PL00005315"},{"key":"10.1124\/jpet.105.089326_bib40","doi-asserted-by":"crossref","unstructured":"Niswender GD, Chen CL, Midgley AR Jr, Meites J, and Ellis S (1969) Radioimmunoassay for rat prolactin. Proc Soc Exp Biol Med 130: 793\u2013797.","DOI":"10.3181\/00379727-130-33657"},{"key":"10.1124\/jpet.105.089326_bib41","doi-asserted-by":"crossref","unstructured":"Okamura N, Yanai K, Higuchi M, Sakai J, Iwata R, Ido T, Sasaki H, Watanabe T, and Itoh M (2000) Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 129: 115\u2013123.","DOI":"10.1038\/sj.bjp.0702994"},{"key":"10.1124\/jpet.105.089326_bib42","doi-asserted-by":"crossref","unstructured":"Ookuma K, Yoshimatsu H, Sakata T, Fujimoto K, Yoshimatsu H, and Fukagawa K (1989) Hypothalamic sites of neuronal histamine action on food intake by rats. Brain Res 490: 268\u2013275.","DOI":"10.1016\/0006-8993(89)90244-8"},{"key":"10.1124\/jpet.105.089326_bib43","doi-asserted-by":"crossref","unstructured":"Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, and Tollefson GD (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57: 249\u2013258.","DOI":"10.1001\/archpsyc.57.3.249"},{"key":"10.1124\/jpet.105.089326_bib44","doi-asserted-by":"crossref","unstructured":"Robertson GS and Fibiger HC (1996) Effects of olanzapine on regional c-Fos expression in rat forebrain. Neuropsychopharmacology 14: 105\u2013110.","DOI":"10.1016\/0893-133X(95)00196-K"},{"key":"10.1124\/jpet.105.089326_bib45","doi-asserted-by":"crossref","unstructured":"Robertson GS, Matsumura H, and Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271: 1058\u20131066.","DOI":"10.1016\/S0022-3565(25)23800-9"},{"key":"10.1124\/jpet.105.089326_bib46","unstructured":"Rourke C, Starr KR, and Jones DNC (2004) The effect of acute and chronic administration of olanzapine on prolactin levels in rats (Abstract). J Psychopharmacol 18: 70."},{"key":"10.1124\/jpet.105.089326_bib47","doi-asserted-by":"crossref","unstructured":"Ryan MCM, Collins P, and Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-na\u00efve patients with schizophrenia. Am J Psychiatry 160: 284\u2013289.","DOI":"10.1176\/appi.ajp.160.2.284"},{"key":"10.1124\/jpet.105.089326_bib48","doi-asserted-by":"crossref","unstructured":"Sakata T, Ookuma K, Fukagawa K, Fujimoto K, Yoshimatsu H, Shiraishi H, and Wada H (1988) Blockade of the histamine H1 receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 441: 403\u2013407.","DOI":"10.1016\/0006-8993(88)91423-0"},{"key":"10.1124\/jpet.105.089326_bib49","doi-asserted-by":"crossref","unstructured":"Seeman P, Lee T, Chau-Wong M, and Wong K (1976) Antipsychotic drug doses and neuroleptic\/dopamine receptors. Nature (Lond) 261: 717\u2013719.","DOI":"10.1038\/261717a0"},{"key":"10.1124\/jpet.105.089326_bib50","doi-asserted-by":"crossref","unstructured":"Silvestre JS and Prous J (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27: 289\u2013304.","DOI":"10.1358\/mf.2005.27.5.908643"},{"key":"10.1124\/jpet.105.089326_bib51","doi-asserted-by":"crossref","unstructured":"Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudalier S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, et al. (2003) Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 88: 5875\u20135880.","DOI":"10.1210\/jc.2002-021884"},{"key":"10.1124\/jpet.105.089326_bib52","doi-asserted-by":"crossref","unstructured":"Stockton ME and Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacol 14: 97\u2013105.","DOI":"10.1016\/0893-133X(94)00130-R"},{"key":"10.1124\/jpet.105.089326_bib53","doi-asserted-by":"crossref","unstructured":"Sundquist SJ and Nisenbaum LK (2005) Fast Fos: rapid protocols for single- and double-labeling c-Fos immunohistochemistry in fresh frozen brain sections. J Neurosci Methods 141: 9\u201320.","DOI":"10.1016\/j.jneumeth.2004.05.007"},{"key":"10.1124\/jpet.105.089326_bib54","doi-asserted-by":"crossref","unstructured":"Swillens S (1992) How to estimate the total receptor concentration when the specific radioactivity of the ligand is unknown. Trends Pharmacol Sci 13: 430\u2013434.","DOI":"10.1016\/0165-6147(92)90139-W"},{"key":"10.1124\/jpet.105.089326_bib55","doi-asserted-by":"crossref","unstructured":"Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, and Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (Lond) 374: 542\u2013546.","DOI":"10.1038\/374542a0"},{"key":"10.1124\/jpet.105.089326_bib56","doi-asserted-by":"crossref","unstructured":"Tran VT, Chang RSL, and Snyder SH (1978) Histamine H1 receptor identified in mammalian brain membranes with [3H]mepyramine. Proc Natl Acad Sci USA 75: 6290\u20136294.","DOI":"10.1073\/pnas.75.12.6290"},{"key":"10.1124\/jpet.105.089326_bib57","doi-asserted-by":"crossref","unstructured":"Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, et al. (2000) Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 57: 841\u2013849.","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"10.1124\/jpet.105.089326_bib58","unstructured":"Tuomisto J and Mannisto P (1985) Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 37: 249\u2013257."},{"key":"10.1124\/jpet.105.089326_bib59","doi-asserted-by":"crossref","unstructured":"Turrone P, Kapur S, Seeman MV, and Flint AJ (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159: 133\u2013135.","DOI":"10.1176\/appi.ajp.159.1.133"},{"key":"10.1124\/jpet.105.089326_bib60","doi-asserted-by":"crossref","unstructured":"Uhlen S, Porter AC, and Neubig RR (1994) The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther 271: 1558\u20131565.","DOI":"10.1016\/S0022-3565(25)24043-5"},{"key":"10.1124\/jpet.105.089326_bib61","unstructured":"Wirshing DA (2001) Adverse effects of atypical antipsychotics. J Clin Psychiatry 62: 7\u201310."},{"key":"10.1124\/jpet.105.089326_bib62","doi-asserted-by":"crossref","unstructured":"Yamamura HI and Snyder SH (1974) Muscarinic cholinergic binding in rat brain. Proc Natl Acad Sci 71: 1725\u20131729.","DOI":"10.1073\/pnas.71.5.1725"},{"key":"10.1124\/jpet.105.089326_bib63","unstructured":"Zgombick JM, Weinshank RL, Macchi M, Schechter LE, Branchek TA, and Hartig PR (1991) Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype. Mol Pharmacol 40: 1036\u20131042."}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524323729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524323729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.105.089326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:42:30Z","timestamp":1740001350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524323729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0022356524323729"],"URL":"https:\/\/doi.org\/10.1124\/jpet.105.089326","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4 H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.105.089326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}